Condition
Relapsed/Refractory SCLC clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Relapsed/Refractory SCLC clinical trials that are recruiting, in China. By phase: Phase 1/2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 1Country
All recruiting trials (2)
-
Adaptive Dual-Target CAR-NK Therapy for Relapsed or Refractory SCLC
This trial tests three dual-target CAR-NK cell products to see if they are safe and show early signs of activity in adults with relapsed or refractory small cell lung cancer.
-
Adaptive Phase 1/2 testing dual-target CAR‑NK cells for relapsed or refractory small cell lung cancer
This trial tests off-the-shelf dual-target CAR‑NK cell therapy in adults with relapsed or refractory extensive-stage small cell lung cancer to see if it is safe and can shrink tumors.
Related topics
Quick answers
How many Relapsed/Refractory SCLC clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.